Zopiclone is one of those medicines that is everywhere in some countries and nonexistent in others. In the United Kingdom, Canada, Australia, much of Europe and parts of Asia, it is a familiar sleeping tablet, sold under names such as Imovane and Zimovane. In the United States it is not approved at all, though its close chemical relative, eszopiclone (Lunesta), is.
That patchwork matters for drivers, because the rules, advice and legal exposure differ depending on where you live. But the biology does not change at a border. Zopiclone next-morning impairment is among the best-documented residual effects of any sleeping pill, and it is one reason regulators in several countries have asked prescribers to use lower doses.
Rather than walking through the topic as a simple list of warnings, this article is organized around the situations drivers actually face: the commuter, the night-shift worker, the older driver, the person who only takes a tablet “now and then,” and the traveler who crosses borders. In between, we cover what the research measured, what Canada and the UK say, and how to talk to a clinician about safer options.
This article is general information, not personal medical advice. Do not change your prescribed dose or stop zopiclone suddenly without speaking to your prescriber.
Zopiclone in 60 Seconds
- Zopiclone is a “Z-drug” sedative-hypnotic prescribed for short-term insomnia.
- It enhances GABA activity in the brain, which quiets neural firing and promotes sleep.
- Driving studies using a standardized highway test have found that a 7.5 mg dose causes moderate to severe impairment the next morning, tested roughly 10 to 11 hours after taking it.
- Health Canada lowered recommended doses in 2014 and prescribers are advised to counsel patients to wait at least 12 hours before driving or doing tasks that need full alertness.
- Zopiclone is the “positive control” in many driving studies, meaning researchers use it as a known impairing drug to check their tests are sensitive.
- Many people do not feel impaired while objectively performing worse.
Zopiclone, Eszopiclone and Imovane: Clearing Up the Names
Because the names are similar, a quick glossary helps.
| Name | What it is | Where you will see it |
|---|---|---|
| Zopiclone | The racemic mixture, containing two mirror-image forms of the molecule | UK, Canada, Australia, Europe, parts of Asia |
| Eszopiclone (Lunesta) | The single “S” form of zopiclone, the more active half | United States and some other markets |
| Imovane, Zimovane | Common brand names for zopiclone | Canada, UK and elsewhere, depending on the market |
Because eszopiclone is the active component of zopiclone, the two share a risk profile. When the FDA assessed next-day impairment with Lunesta, it compared the effect of a 3 mg dose to zopiclone 7.5 mg and noted the size of the impairment was similar. If you want the U.S. perspective, see our article on Lunesta and next-morning impairment.
What the Driving Research Measured
The best evidence on how sleeping pills affect driving comes from standardized on-road tests, often conducted on a public highway with an instructor beside the participant. The main measure is something called standard deviation of lateral position, which reflects how much a vehicle weaves within its lane. It is a sensitive marker of driving impairment and has been calibrated against blood alcohol concentration.
A pooled analysis published in 2014 in the journal Clinical Therapeutics combined four placebo-controlled studies of zopiclone 7.5 mg. In all of them, driving was tested the next morning, between 10 and 11 hours after the dose. The authors concluded that zopiclone 7.5 mg causes moderate to severe impairment of driving performance, and the paper noted that zopiclone is among the most frequently prescribed hypnotics in many European countries, Canada and Japan. You can read the abstract on PubMed.
Separate Norwegian research linked blood zopiclone concentrations with signs of impairment in drivers, finding that impairment became more likely as concentrations rose and reporting a pattern comparable to that seen with alcohol. Together, these lines of evidence explain why drug regulators treat zopiclone as a clear driving risk rather than a theoretical one.
For comparison, a very short-acting sleeping pill such as zaleplon is cleared so quickly that on-road tests show little or no effect several hours later. Our article on Sonata and next-morning impairment explains why half-life makes such a difference.
Scenario 1: The Daily Commuter
Priya takes zopiclone most weeknights. She goes to bed at 10:30 p.m., wakes at 6:30 a.m., and leaves the house at 7:15 for a 40-minute motorway commute. (Priya is a fictional composite used for illustration.)
From the study design above, her 7:15 departure sits about 8.5 hours after dosing, and the trip stretches to roughly 9.5 hours. This is well inside the window in which standardized highway tests detected moderate to severe impairment at 7.5 mg. Her dose might be lower, and the effect would then be smaller, but the principle holds: a standard dose followed by a standard commute is exactly the pattern in which problems arise.
What a clinician might discuss with Priya:
- Whether she needs zopiclone every night or could use it only on selected nights.
- Whether a lower dose, as recommended by Health Canada and similar authorities, would still help her sleep.
- Whether adjusting her schedule, for example working from home after a medicated night, is realistic.
- Whether cognitive behavioral therapy for insomnia could reduce her reliance on the tablet.
Scenario 2: The Night-Shift Worker
Marcus finishes a night shift at 7 a.m., takes zopiclone at 8 a.m. to sleep through the day, and then commutes back to work at 8 p.m. The clock on the wall says it is evening; the clock in his bloodstream says only twelve hours have passed. (Marcus is a fictional composite.)
The right way to think about timing is always to count from the moment you swallowed the tablet. A twelve-hour gap is the minimum that Canadian guidance describes, and it is the minimum, not a guarantee. Marcus should also be aware that sleeping in daylight is typically lighter and shorter, which can mean he wakes before the drug has cleared.
Scenario 3: The Older Driver
Older adults are generally more sensitive to sedatives and clear drugs more slowly. Regulators and geriatric guidelines advise lower doses for people over 65. Health Canada’s dose changes included specific recommendations for older people, and lower starting doses are standard in other countries too.
For an older driver, the concern is twofold. First, the morning-after driving risk is higher. Second, a person who gets up at night to use the bathroom while sedated has a higher risk of falls and fractures. A clinician may recommend a lower dose, a shorter course, or an alternative strategy altogether. Our guide on natural ways to improve insomnia offers non-drug steps that older adults can often combine with professional advice.
Scenario 4: The “Only Now and Then” User
People who use zopiclone occasionally sometimes assume they are safer, because they are not building up a habit. In one sense that is true: intermittent use reduces the risk of dependence. But for driving, occasional users can be more vulnerable than regular users, because they have had no opportunity to adapt to the sedative effect and are more likely to feel the grogginess. They also tend to take zopiclone on unusual nights, such as before a flight or a stressful event, and then drive the next morning to an unfamiliar destination.
The takeaway is that infrequent use does not remove the need for a plan. The same timing rule applies on a “one-off” night as on a regular one.
Scenario 5: The Traveler Crossing Borders
Because zopiclone is not approved in the United States, travellers face practical issues. Carrying the tablet into a country where it is not authorized can raise legal or customs questions, and the rules vary. Check the regulations for your destination, carry the medicine in its original labeled packaging, and consider bringing a copy of your prescription. If you take a different sleeping tablet while travelling, remember that jet lag, unfamiliar cars and unfamiliar roads add extra demands on attention, so the next-morning driving risk can be higher than at home.
What the Law Says: United Kingdom, Canada and Beyond
This section is general information, not legal advice. Laws change, so check official sources for your location.
United Kingdom
England and Wales introduced a law in March 2015 that created an offence of driving with certain drugs above a specified blood limit, regardless of whether driving was impaired. The list includes illegal drugs set at near-zero levels, and a handful of prescription medicines, among them clonazepam, diazepam, lorazepam, temazepam, morphine and methadone. In the lists we reviewed, zopiclone does not appear with a numeric limit. That does not make driving after zopiclone safe or lawful if you are impaired: the long-standing offence of driving while unfit through drugs still applies to any medicine, including those prescribed by a doctor. Police can carry out field impairment assessments and can obtain blood samples. The official overview is on GOV.UK.
A “medical defence” exists in the UK for certain specified drugs if you took them as prescribed and are not impaired, but it does not protect a driver who is actually impaired. If you are given zopiclone, the leaflet and your pharmacist will normally tell you not to drive if you feel drowsy, and you should take that advice literally.
Canada
In 2014 Health Canada released new dosing recommendations for zopiclone to reduce next-day impairment, informed by evidence that effects can persist for up to 11 hours after an evening dose. Provincial pharmacy guidance, such as that from British Columbia’s PharmaCare program, advises counselling patients to wait at least 12 hours before driving or doing other tasks that require full alertness. You can read British Columbia’s summary in this PharmaCare bulletin (PDF).
Elsewhere
Many jurisdictions have general impaired-driving laws that cover prescription drugs, and some have specific limits. In most places, a prescription is not a defence if your driving is affected. Check your local transport or health authority for current rules, and ask a pharmacist.
Why Zopiclone Lingers: A Plain-English Pharmacology Note
Zopiclone reaches peak levels in the blood within roughly an hour or two and has an elimination half-life of around five hours in healthy adults, longer in older people and in those with liver disease. The mechanics are less important than the practical consequence: after a full night, a sizeable proportion of the drug may remain, and the active effect on attention and reaction time can outlast the sedation you consciously feel.
Another feature of zopiclone is its metallic or bitter taste, which many users notice the following morning. That taste is a side effect and not a sign of how much drug remains, so do not use it as a gauge.
Several factors can raise morning levels:
- Higher doses, which is why lower doses are preferred.
- Older age and reduced liver or kidney function.
- Medicines that slow breakdown, including some antibiotics and antifungals.
- Alcohol and other sedating drugs, which add to impairment even if they do not change the blood level of zopiclone.
The Awareness Gap: Why “I’m Fine” Is Not Good Enough
When the FDA reviewed next-day impairment with the related drug eszopiclone, it highlighted that volunteers did not recognize their own impairment. Researchers sometimes call this the awareness gap, and it appears across many sedative studies. It is probably the single most important reason to treat timing rules as non-negotiable. If you wait until you feel impaired to decide you should not drive, you may already be past the point of reliable self-judgement.
Here are the practical implications:
- Decide before you take the tablet whether you will need to drive early the next day.
- If you will, skip the dose, reduce it on medical advice, or arrange alternative transport.
- Do not use caffeine, cold air or loud music as safety tools.
- If a passenger says you seem off, believe them.
A Simple Decision Guide for Mornings After Zopiclone
The questions below are not a diagnostic tool. They are a structured way to slow down and make a deliberate choice.
| Question | If “yes” |
|---|---|
| Has it been fewer than 12 hours since I took zopiclone? | Avoid driving or arrange another way to travel |
| Did I sleep fewer than seven to eight hours? | Treat this as a higher-risk morning and delay driving |
| Did I drink alcohol or take another sedating medicine? | Do not drive unless you have clear advice that it is safe |
| Do I feel foggy, clumsy, forgetful or slow? | Do not drive |
| Am I older, or do I have liver problems? | Discuss a lower dose and stricter timing with a clinician |
| Is the drive long, at night or on a motorway? | Apply a larger safety margin |
Complex Sleep Behaviours and Other Risks
Beyond morning impairment, Z-drugs carry other safety warnings. Sleepwalking, sleep-eating and sleep-driving have been reported with this class of medicines. The U.S. FDA reviewed such events with eszopiclone, zaleplon and zolpidem and added a boxed warning to those drugs; similar cautions appear in many countries’ product information for zopiclone. Other known issues include memory problems, confusion, falls in older adults, dependence with long-term use, and withdrawal or rebound insomnia if the tablet is stopped abruptly after prolonged use.
Mixing zopiclone with opioids, benzodiazepines, alcohol or other sedatives can slow breathing and is dangerous. Always tell your prescriber about everything you take, including over-the-counter and herbal products. Our article on Ambien vs Xanax explains why combining sedating drugs is risky.
Talking With Your Clinician About Safer Options
It is reasonable to ask whether zopiclone is the best option for you, especially if you drive for a living. Consider raising these points:
- Duration: Z-drugs are generally intended for short-term use, usually a few weeks at most. Ask what your end date is.
- Dose: Ask whether the lowest effective dose is appropriate.
- Timing: Ask for explicit written guidance about how long to wait before driving.
- Underlying causes: Ask about screening for sleep apnea, depression, anxiety, pain and restless legs.
- Alternatives: Options may include CBT-I, sleep hygiene, treating the root cause, or different medicines with different risk profiles. For example, see our comparison of Lunesta vs trazodone and our overview of how Rozerem works on melatonin receptors.
How Family, Friends and Passengers Can Help
Because impaired people are poor judges of their own performance, a second pair of eyes is a genuine safety tool. If you live with someone who takes zopiclone, a few simple agreements can prevent a bad morning.
- Agree on a “no-questions” rule. If a family member says you seem slow, forgetful or unsteady, you hand over the keys without debate.
- Offer lifts without making it a favour. People are more likely to accept help if it is framed as routine rather than as a rescue.
- Notice patterns. If someone is repeatedly confused, clumsy or sleepy in the morning, encourage them to talk to their prescriber rather than waiting for something to go wrong.
- Look out for night-time behaviour. Sleepwalking, eating in a daze or unexplained messages are reasons to call a clinician promptly.
- Keep the medicine safely stored, away from children and visitors, and never share tablets with others.
Keeping a Simple Driving-Safety Diary
If you take zopiclone regularly, a two-week diary can reveal patterns that a single appointment might miss. It takes less than a minute each day. Record:
- The time you took the tablet and the dose.
- The time you went to bed and woke up.
- How you felt on waking: clear, groggy, clumsy or forgetful.
- Whether you drove, and how many hours had passed since the dose.
- Alcohol or other medicines taken the previous evening.
- Any near misses, lapses in attention or comments from other people.
Take the diary to your next appointment. A prescriber who can see that your worst mornings follow five-hour nights, or that a lower dose gives you the same sleep with a clearer head, is in a much better position to adjust your treatment. The diary also helps you decide honestly whether the benefits of the tablet outweigh its risks for your particular schedule.
Information for Employers, Fleet Managers and Occupational Health
Zopiclone is not only a personal medication issue. Where driving is part of the job, safety policies need to account for prescribed sedatives as well as alcohol and illegal drugs. Sensible policies tend to share a few features:
- A clear requirement that employees tell occupational health, in confidence, about medicines that may affect driving.
- A culture where reporting a sedating medicine leads to support, such as temporary duty changes, rather than punishment.
- Guidance that treats “time since dose” as the important number, especially for shift workers.
- Access to confidential advice from a pharmacist or occupational physician.
Drivers who rely on their licence for their living sometimes hide a sleeping problem because they fear the consequences. That is understandable, but it removes the chance to find a safer treatment. A frank discussion with a clinician is usually the better route.
Frequently Asked Questions
How long should I wait to drive after taking zopiclone?
Canadian provincial guidance advises at least 12 hours, drawn from Health Canada’s findings that impairment can last up to 11 hours after an evening dose. Your prescriber may advise longer depending on your dose, age and health.
Is zopiclone legal to drive on in the UK?
Taking a prescribed medicine is not an offence in itself, and zopiclone is not among the drugs with a specified numeric limit in the lists we reviewed. However, driving while impaired by any drug, including a prescribed one, is an offence. Check GOV.UK for the latest rules.
Why is zopiclone not available in the United States?
It was never approved by the FDA as zopiclone itself. A single-isomer version, eszopiclone, was approved as Lunesta instead.
Does zopiclone cause a bitter taste in the morning?
Yes, a metallic or bitter taste is a commonly reported effect. It is not a reliable measure of drug level or impairment.
Is 3.75 mg safer than 7.5 mg for driving?
Lower doses leave less drug in your system the next day and are generally preferred, especially for older adults and people with liver problems. They reduce, but do not eliminate, the risk, so timing rules still apply.
Can I take zopiclone and drive the same evening?
No. Zopiclone is meant to be taken immediately before bed. Do not drive or operate machinery after taking it until the effects have fully worn off.
What if I take zopiclone and wake up in the night?
Do not take another tablet and do not drive. Levels are still high during the night, and a second dose raises the risk of heavy impairment the next day.
Is it safe to combine zopiclone and alcohol?
No. Alcohol adds to sedation, worsens coordination and increases the risk of dangerous breathing problems. Avoid the combination.
Key Takeaways
- Highway driving tests show zopiclone 7.5 mg causes moderate to severe impairment 10 to 11 hours after dosing.
- Health Canada lowered dose recommendations, and provincial guidance advises waiting at least 12 hours before driving.
- Feeling alert is not a reliable safety check, so plan around timing, dose and sleep length.
- Laws vary by country, but impaired driving is an offence nearly everywhere, even when the medicine is prescribed.
- If you drive for work or have a long commute, talk to a clinician about the lowest dose, the shortest duration and non-drug treatments.
Sources and Further Reading
- PubMed: Zopiclone’s residual effects on actual driving performance: pooled analysis of four placebo-controlled studies (Clinical Therapeutics, 2014)
- British Columbia PharmaCare: Zopiclone dose, next-day impairment, tablet strengths (PDF)
- GOV.UK: Drug driving law
- U.S. FDA: Drug Safety Communication on eszopiclone (Lunesta)
Medical disclaimer: This content is for general education and is not a substitute for professional medical advice, diagnosis or treatment. Follow the guidance of your prescriber and the product information approved in your country.
